Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives Consensus Recommendation of "Buy" from Analysts

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) have been given an average recommendation of "Buy" by the seven brokerages that are covering the stock, MarketBeat reports. Seven investment analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $23.63.

A number of brokerages recently weighed in on ATEC. Canaccord Genuity Group restated a "buy" rating and set a $25.00 target price on shares of Alphatec in a report on Wednesday, March 20th. HC Wainwright reiterated a "buy" rating and issued a $20.00 price objective on shares of Alphatec in a report on Monday, March 4th. Needham & Company LLC upped their price objective on shares of Alphatec from $22.00 to $23.00 and gave the company a "buy" rating in a report on Thursday, March 28th. Finally, Wells Fargo & Company began coverage on shares of Alphatec in a report on Friday, February 9th. They issued an "overweight" rating and a $26.00 price objective on the stock.

Insider Buying and Selling

In related news, CFO John Todd Koning sold 121,601 shares of the company's stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $13.30, for a total transaction of $1,617,293.30. Following the completion of the sale, the chief financial officer now owns 430,856 shares of the company's stock, valued at $5,730,384.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, CFO John Todd Koning sold 121,601 shares of the stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $13.30, for a total value of $1,617,293.30. Following the completion of the transaction, the chief financial officer now owns 430,856 shares of the company's stock, valued at $5,730,384.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Scott Lish sold 11,963 shares of the stock in a transaction dated Wednesday, February 21st. The stock was sold at an average price of $15.34, for a total transaction of $183,512.42. Following the completion of the transaction, the chief operating officer now directly owns 538,240 shares of the company's stock, valued at approximately $8,256,601.60. The disclosure for this sale can be found here. Insiders sold 247,569 shares of company stock valued at $3,490,745 over the last quarter. 29.12% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. AE Wealth Management LLC acquired a new position in shares of Alphatec in the third quarter valued at approximately $423,000. Mach 1 Financial Group LLC acquired a new position in shares of Alphatec in the third quarter valued at approximately $421,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Alphatec by 23.8% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,120 shares of the medical technology company's stock valued at $157,000 after buying an additional 2,331 shares during the period. BluePath Capital Management LLC acquired a new position in shares of Alphatec in the third quarter valued at approximately $29,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Alphatec by 10.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 44,509 shares of the medical technology company's stock valued at $577,000 after buying an additional 4,210 shares during the period. Institutional investors own 66.35% of the company's stock.

Alphatec Stock Up 1.1 %

Shares of NASDAQ ATEC traded up $0.14 during midday trading on Tuesday, reaching $12.93. The company's stock had a trading volume of 1,347,768 shares, compared to its average volume of 1,626,751. The company has a current ratio of 2.86, a quick ratio of 1.99 and a debt-to-equity ratio of 6.54. Alphatec has a fifty-two week low of $8.66 and a fifty-two week high of $19.14. The stock has a market capitalization of $1.78 billion, a price-to-earnings ratio of -8.33 and a beta of 1.55. The stock has a 50 day simple moving average of $13.88 and a 200-day simple moving average of $13.46.

Alphatec (NASDAQ:ATEC - Get Free Report) last posted its quarterly earnings data on Tuesday, February 27th. The medical technology company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.09). The firm had revenue of $138.00 million for the quarter, compared to the consensus estimate of $131.90 million. The firm's revenue was up 30.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.33) EPS. Equities research analysts predict that Alphatec will post -1.1 earnings per share for the current year.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.